Stephen Gordon Net Worth

The estimated Net Worth of Stephen Gordon is at least $7.5 Milion dollars as of 3 June 2024. Mr Gordon owns over 2,060 units of TransMedics stock worth over $3,359,258 and over the last 6 years he sold TMDX stock worth over $3,624,860. In addition, he makes $512,341 as CFO. Treasurer & Sec. at TransMedics.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Gordon TMDX stock SEC Form 4 insiders trading

Mr has made over 29 trades of the TransMedics stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 2,060 units of TMDX stock worth $79,228 on 3 June 2024.

The largest trade he's ever made was selling 20,000 units of TransMedics stock on 29 May 2024 worth over $2,828,000. On average, Mr trades about 7,491 units every 42 days since 2019. As of 3 June 2024 he still owns at least 23,359 units of TransMedics stock.

You can see the complete history of Mr Gordon stock trades at the bottom of the page.

Mr. Stephen Gordon biography

Stephen Gordon is the CFO. Treasurer & Sec. at TransMedics.

What is the salary of Mr Gordon?

As the CFO. Treasurer & Sec. of TransMedics, the total compensation of Mr Gordon at TransMedics is $512,341. There are 4 executives at TransMedics getting paid more, with Waleed Hassanein having the highest compensation of $3,159,300.

How old is Mr Gordon?

Mr Gordon is 53, he's been the CFO. Treasurer & Sec. of TransMedics since . There are 10 older and 5 younger executives at TransMedics. The oldest executive at TransMedics Group, Inc. is James Tobin, 75, who is the Independent Chairman of the Board.

What's Mr Gordon's mailing address?

Stephen's mailing address filed with the SEC is C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, ANDOVER, MA, 01810.

Insiders trading at TransMedics

Over the last 6 years, insiders at TransMedics have traded over $99,976,312 worth of TransMedics stock and bought 154,333 units worth $3,250,328 . The most active insiders traders include Edwin M Jr Kania, Waleed H Hassanein oraz James R Tobin. On average, TransMedics executives and independent directors trade stock every 10 days with the average trade being worth of $2,982,476. The most recent stock trade was executed by Tamer I Khayal on 3 September 2024, trading 2,960 units of TMDX stock currently worth $98,065.

What does TransMedics do?

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.

Complete history of Mr Gordon stock trades at TransMedics

TransMedics executives and stock owners

TransMedics executives and other stock owners filed with the SEC include:

• Waleed Hassanein,
  President, Chief Executive Officer, Director
• Tamer Khayal,
  Chief Commercial Officer
• Dr. Waleed H. Hassanein,
  Founder, MD, CEO, Pres & Director
• Dr. Tamer I. Khayal,
  Chief Commercial Officer
• Stephen Gordon,
  CFO. Treasurer & Sec.
• Stephen Gordon,
  Chief Financial Officer, Treasurer, Secretary
• David Weill,
  Independent Director
• James Tobin,
  Independent Chairman of the Board
• Thomas Gunderson,
  Independent Director
• Edward Basile,
  Independent Director
• Edwin Kania,
  Independent Director
• John Sullivan,
  Vice President - Quality and Engineering
• Miriam Provost,
  Vice President - Global Regulatory Affairs
• Laura Damme,
  Vice President - Clinical Affairs
• John Carey,
  Vice President - Operations
• Susan Goodman,
  VP of HR
• Mark Anderson,
  Sr. Director of Technology Devel.
• Ike Okonkwo,
  VP of Fin. & Accounting
• John F. Carey,
  VP of Operations
• Therapeutics Corp Lung Biot...,
  
• Ventures Fund Iv General Pa...,
  
• Capital Management, L.P.Abr...,
  
• Merilee Raines,
  
• Capital Management, L.P.Abr...,
  
• Rakesh P. Godhani,
  Chief Digital Officer
• Nicholas Corcoran,
  See Remarks
• Stephanie Lovell,
  
• Anil P. Ranganath,
  See remarks